Skip to main content
Ebola outbreak caused by Bundibugyo virus: challenges and priorities for epidemic preparedness and response.
The future of type 1 diabetes therapy.
Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial.
A call to action: the second Lancet Commission on adolescent health and wellbeing.
Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial.
Regional action needed to halt antimalarial drug resistance in Africa.
Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype β-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial.
Societal implications of the Dobbs v Jackson Women's Health Organization decision.
Health-care workforce implications of the Dobbs v Jackson Women's Health Organization decision.
Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium.